Stephen A. Trowbridge
Net Worth
Last updated:
What is Stephen A. Trowbridge net worth?
The estimated net worth of Mr. Stephen A. Trowbridge is at least $9,812,395 as of 8 Oct 2024. He owns shares worth $1,523,311 as insider, has earned $159,184 from insider trading and has received compensation worth at least $8,129,900 in AngioDynamics, Inc..
What is the salary of Stephen A. Trowbridge?
Mr. Stephen A. Trowbridge salary is $812,990 per year as Executive Vice President & Chief Financial Officer in AngioDynamics, Inc..
How old is Stephen A. Trowbridge?
Mr. Stephen A. Trowbridge is 51 years old, born in 1974.
What stocks does Stephen A. Trowbridge currently own?
As insider, Mr. Stephen A. Trowbridge owns shares in one company:
Company | Title | Shares | Price per share | Total value |
---|---|---|---|---|
AngioDynamics, Inc. (ANGO) | Executive Vice President & Chief Financial Officer | 172,711 | $8.82 | $1,523,311 |
What does AngioDynamics, Inc. do?
AngioDynamics, Inc. designs, manufactures, and sells various medical, surgical, and diagnostic devices used by professional healthcare providers for the treatment of peripheral vascular disease and vascular access; and for use in oncology and surgical settings in the United States and internationally. The company provides NanoKnife ablation systems for the surgical ablation of soft tissues; solero microwave tissue ablation systems; and radiofrequency ablation products for ablating solid cancerous or benign tumors. It also offers BioSentry tract sealant systems, IsoLoc Endorectal Balloon's, alatus vaginal balloon packing systems, angiographic catheters, guidewires, percutaneous drainage catheters, and coaxial micro-introducer kits. In addition, the company provides endovascular therapies products in the areas of thrombus management, atherectomy, peripheral products (Core), and venous insufficiency. Additionally, the company offers peripherally inserted central catheters, midline catheters, implantable ports, dialysis catheters, and related accessories and supplies that are used primarily to deliver short-term drug therapies, such as chemotherapeutic agents and antibiotics, into the central venous system under the BioFlo, BioFlo Midline, BioFlo PICC, Xcela PICC, PASV, BioFlo Port, SmartPort, Vortex, LifeGuard, BioFlo DuraMax, and DuraMax names. It sells and markets its products to interventional radiologists, interventional cardiologists, vascular surgeons, urologists, interventional and surgical oncologists, and critical care nurses directly, as well as through distributor relationships. The company was founded in 1988 and is headquartered in Latham, New York.
Stephen A. Trowbridge insider trading
AngioDynamics, Inc.
Mr. Stephen A. Trowbridge has made 2 insider trades between 2015-2024, according to the Form 4 filled with the SEC. Most recently he purchased 1,700 units of ANGO stock worth $9,962 on 8 Oct 2024.
The largest trade he's ever made was exercising 30,242 units of ANGO stock on 19 Jul 2023. As of 8 Oct 2024 he still owns at least 172,711 units of ANGO stock.
AngioDynamics key executives
AngioDynamics, Inc. executives and other stock owners filed with the SEC:
- Mr. Chad T. Campbell (54) Senior Vice President & GM of Vascular Access Global Bus. Unit
- Mr. David D. Helsel (61) Senior Vice President of Global Operations and R&D
- Mr. James C. Clemmer (61) Chief Executive Officer, Pres & Director
- Mr. Stephen A. Trowbridge (51) Executive Vice President & Chief Financial Officer
- Mr. Warren G. Nighan (56) Senior Vice President of Quality & Regulatory Affairs